Aspira Women's Health Files Proxy Statement

TL;DR

Aspira Women's Health (AWH) filed its proxy statement, shareholders vote soon.

AI Summary

Aspira Women's Health Inc. (formerly Vermillion, Inc.) filed a DEFA14A proxy statement on May 10, 2024. This filing concerns the company's annual meeting and related corporate governance matters. The company is involved in in vitro and in vivo diagnostic substances and is incorporated in Delaware.

Why It Matters

This filing provides shareholders with crucial information regarding the company's annual meeting, allowing them to vote on important matters and understand executive compensation and board nominations.

Risk Assessment

Risk Level: low — This is a routine proxy filing (DEFA14A) and does not contain new financial information or significant corporate events.

Key Players & Entities

• Aspira Women's Health Inc. (company) — Registrant
• VERMILLION, INC. (company) — Former company name
• CIPHERGEN BIOSYSTEMS INC (company) — Former company name
• ABIOTIC SYSTEMS (company) — Former company name
• 2835 (dollar_amount) — Standard Industrial Classification code

FAQ

Key Financial Figures

• $0.001 — shall mean the common stock, par value $0.001 per share, of the Company, and all righ
• $400,000 — Non-Employee Director shall not exceed $400,000. 1.5 SharesAvailable . Subject to adj
• $100,000 — bsidiary) exceeds the amount (currently $100,000) established by the Code, such options

Filing Documents

• proxy_supplement_050924.htm (DEFA14A) — 193KB
• 0000950170-24-057335.txt ( ) — 194KB

From the Filing

DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ý Filed by a Party other than the Registrant  Check the appropriate box:  Preliminary Proxy Statement  Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  Definitive Proxy Statement ý Definitive Additional Materials  Soliciting Material under 240.14a-12 Aspira Women’s Health Inc. (Name of Registrant as Specified in its Charter) (Name of Person(s) Filing Proxy Statement, if other than the Registrant) Payment of Filing Fee (Check all boxes that apply): ý No fee required.  Fee paid previously with preliminary materials.  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11. ASPIRA WOMEN’S HEALTH INC. 12117 Bee Caves Road, Building III, Suite 100 Austin, Texas 78738 (512) 519-0400 ______________________ Supplement to Proxy Statement for ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON MAY 13, 2024 ______________________ This supplement, dated May 9, 2024 (this “Supplement”), supplements, and should be read in conjunction with, the proxy statement (the “Proxy Statement”) of Aspira Women’s Health Inc. (the “Company”) filed with the Securities and Exchange Commission (the “SEC”) on April 1, 2024, relating to the Company’s 2024 Annual Meeting of Stockholders to be held at 12:00 p.m. Eastern time on Monday, May 13, 2024 (the “Annual Meeting”). The primary purpose of this Supplement is to provide a copy of the Aspira Women’s Health Inc. 2019 Stock Incentive Plan, as amended by the Amendment (as defined in the Proxy Statement), as Appendix A to the Proxy Statement. Appendix A was inadvertently omitted from the Proxy Statement and is included herein. In addition, as previously disclosed in our Form 8-K filed with the SEC on April 26, 2024, on April 22, 2024, Minh Merchant, the Company’s General Counsel, Chief Compliance Officer, and Corporate Secretary, notified the Company that she would resign from these roles with the Company effective May 6, 2024. This Supplement does not change the proposals to be voted on at the Annual Meeting or the recommendations of the Company’s Board of Directors with respect to such proposals, in each case, as described in the Proxy Statement. Except as explicitly provided herein, this Supplement does not revise or update any of the information set forth in the Proxy Statement. If you have already submitted your proxy, or voted by telephone or Internet, you do not need to take additional action unless you wish to revoke or change your vote. If you wish to revoke or change your vote, you may do so by using the methods described in the Proxy Statement. If you have not already submitted your proxy, or voted by telephone or Internet, you may do so by returning your proxy card or voting instruction form, to the extent you received hard copies of the proxy materials, or by voting over the telephone or the Internet. The Board of Directors continues to recommend that stockholders vote “FOR” the approval of the Amendment to the Aspira Women’s Health Inc. 2019 Stock Incentive Plan. Appendix A ASPIRA WOMEN’S HEALTH INC. 2019 STOCK INCENTIVE PLAN AS AMENDED BY THE AMENDMENT ASPIRA WOMEN’S HEALTH INC. 2019 STOCK INCENTIVE PLAN  Adopted by the Board of Directors: May 9, 2019 Approved by the Stockholders: June 18, 2019 Amended by the Board [1] : June 23, 2022 Amended by the Board: March 16, 2023 Approved by the Stockholders: May 9, 2023 Amended by the Board: March 8, 2024 Approved by the Stockholders: ________, 2024 I. INTRODUCTION 1.1 Purposes . The purposes of the Aspira Women’s Health Inc. 2019 Stock Incentive Plan (this “ Plan ”) are (i) to align the interests of the Company’s stockholders and the recipients of awards under this Plan by increasing the proprietary interest of such recipients in the Company’s growth and success, (ii) to advance the interests of the Company by attracting and retaining Non-Employee Directors, officers, other employees, consultants, independent contractors and agents and (iii) to motivate such persons to act in the long‑term best interests of the Company and its stockholders. 1.2 Certain Definitions . “ Agreement ” shall mean the written or electronic agreement evidencing an award hereunder between the Company and the recipient of such award. “ Board ” shall mean the Board of Directors of the Company. “ Change in Control ” shall have the meaning set forth in Se

View Full Filing

View this DEFA14A filing on SEC EDGAR